avacincaptad pegol   Click here for help

GtoPdb Ligand ID: 12857

Synonyms: ARC-1905 | ARC1905 | Izervay® | Zimura
Approved drug Immunopharmacology Ligand
avacincaptad pegol is an approved drug (FDA (2023))
Compound class: Nucleic acid
Comment: Avacincaptad pegol (ARC-1905) is a pegylated RNA aptamer that selectively binds to complement C5 and prevents its cleavage into C5a and C5b. This action inhibits activation of inflammasomes and the formation of membrane attack complexes (MAC).

In the sequence presented 'dfl' represents 2'-deoxy-2'-fluoro-modified bases and 'm' represents 2'-O-methyl modifications. The PEG is added at the 3' 'R'.
No information available.
Summary of Clinical Use Click here for help
Avacincaptad pegol (ARC-1905) was progressed to clinical evaluations to determine efficacy in age-related macular degeneration (AMD) [1]. It met its primary endpoints in two studies. The FDA granted approval for the treament of geographic atrophy (secondary to AMD) in August 2023. This drug is administered as an intravitreal injection.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04435366 A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) Phase 3 Interventional IVERIC bio, Inc.
NCT02686658 Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Phase 2/Phase 3 Interventional IVERIC bio, Inc.
NCT03364153 Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) Phase 2 Interventional IVERIC bio, Inc.